Session » Systemic Lupus Erythematosus - Clinical Aspects and Treatment Poster Session I

Date: Sunday, November 8, 2015

Time: 9:00AM-11:00AM

Meeting: 2015 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 737

A Paper Patient-Based Flare Study in SLE

9:00AM-11:00AM: Abstract Number: 782

A Proposal for Assessing Systemic Lupus Erythematosus Activity By a Multimodal Instrument That Includes Clinical Variables, Physician Assessment and Modification of Treatment

9:00AM-11:00AM: Abstract Number: 752

A Strong Association Between Gout and Diuretic Use Among Lupus Patients

9:00AM-11:00AM: Abstract Number: 790

An Intervention to Improve Quality of Life for African-American Lupus Patients

9:00AM-11:00AM: Abstract Number: 786

Anti-Carbamylated Protein Antibodies Identify Systemic Lupus Erythematosus Patients with Erosive Arthritis: Analysis of a Regional Swedish Register

9:00AM-11:00AM: Abstract Number: 774

Anti-Nuclear Antibodies Have High Sensitivity for Systemic Lupus Erythematosus: Results of a Systematic Literature Review and Meta-Regression of Diagnostic Data

9:00AM-11:00AM: Abstract Number: 781

Anti-Nucleosome Antibodies Versus Anti-DNA Antibodies in the Diagnosis and Monitoring of Activity of Systemic Lupus Erytematosus

9:00AM-11:00AM: Abstract Number: 726

Associates of Pleurisy of Pericarditis in Systemic Lupus Erythematosus (SLE)

9:00AM-11:00AM: Abstract Number: 778

Associations Between Autoantibodies and Clinical Manifestations in Systemic Lupus Erythematosus: Data from a Multiethnic Latin American Cohort

9:00AM-11:00AM: Abstract Number: 728

Autoimmune Hemolytic Anemia and Thrombocytopenia in a Single Centre Cohort of Patients with Systemic Lupus Erythematosus from Turkey : Clinical Associations and Effect on Disease Damage and Survival

9:00AM-11:00AM: Abstract Number: 756

Axl, Ferritin, IGFBP2 and TNFR2 As Biomarkers in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 743

Behavior of Complement Levels and Risk of Organ Involvement in SLE Patients

9:00AM-11:00AM: Abstract Number: 750

Belimumab for Systemic Lupus Erythematosus: A Cochrane Systematic Review and Meta-Analysis

9:00AM-11:00AM: Abstract Number: 735

Belimumab Reduces the Frequency of Flares and Prevents Damage Progression in SLE Patients: Experience in a Clinical Practice Setting

9:00AM-11:00AM: Abstract Number: 720

Biomarkers in Lupus Nephritis: The Possible Role of Serum Cystatin C, Serum β2-Microglobulin, Urinary Î±1-Microglobulin and Albuminâ�„Creatinine Ratio

9:00AM-11:00AM: Abstract Number: 722

Biomarkers/Pathways Discovery of Lupus Nephritis By Urine Proteomics

9:00AM-11:00AM: Abstract Number: 719

Cell of Origin of Diffuse Large B-Cell Lymphoma (DLBCL) in Patients with Systemic Lupus Erythematosus (SLE)

9:00AM-11:00AM: Abstract Number: 745

Changes in Serum Albumin Levels Correlate Highly with Severity and Activity of SLE

9:00AM-11:00AM: Abstract Number: 770

Circulating Levels of iC3b and C3 Correlate with Sledai-2K Responder Index-50 (S2K RI-50) Disease Activity Scores: The Castle (Complement Activation Signatures in Systemic Lupus Erythematosus) Study

9:00AM-11:00AM: Abstract Number: 766

Clinical and Immunological Characteristics of 150 Systemic Lupus Erythematosus Patients in Urban Jamaica

9:00AM-11:00AM: Abstract Number: 773

Clinical Evaluation of Patients with Positive Antibodies to Extractable Nuclear Antigens but Negative ANA

9:00AM-11:00AM: Abstract Number: 765

Clinical Improvements in Systemic Lupus Erthematosus Are Correlated to Cellular and Soluble Biomarkers in Classical Complement Pathway

9:00AM-11:00AM: Abstract Number: 748

Comparison of Systemic Lupus Erythematosus in 3 Different Asian Ethnic Groups: Results from the 1000 Faces of Lupus Cohort

9:00AM-11:00AM: Abstract Number: 736

Complement Activation As a Marker for Increased Thrombosis Risk in SLE Patients with Antiphospholipid Antibodies

9:00AM-11:00AM: Abstract Number: 771

Convergent Validity of New Disease Assessment Instruments in Systemic Lupus Erythematosus in Relation to Sledai-2K

9:00AM-11:00AM: Abstract Number: 731

Damage and Mortality in SLE: Cluster Analysis of Patients from SLE Registry from the Spanish Society for Rheumatology (RELESSER)

9:00AM-11:00AM: Abstract Number: 732

Decreased Disease Activity and Corticosteroid Usage and Improved Quality of Life during Belimumab Treatment in Patients with Systemic Lupus Erythematosus – a Prospective Real-Life Observational Study

9:00AM-11:00AM: Abstract Number: 747

Depletion of Serum Soluble CD40L Characterizes the Association Between Systemic Lupus Erythematosus and Thrombotic Thrombocytopenic Purpura: Longitudinal, Single-Center Study

9:00AM-11:00AM: Abstract Number: 789

Direct Coombs Positivity in SLE

9:00AM-11:00AM: Abstract Number: 734

Disease Patterns, Flare Incidence and Organ Damage Among Filipino Patients with Systemic Lupus Erythematosus: a One-Year Observational Study

9:00AM-11:00AM: Abstract Number: 758

Dominican Patients with Systemic Lupus Erythematosus Residing in New York City Have a Higher SLICC/ACR Damage Index Than Those in the Dominican Republic

9:00AM-11:00AM: Abstract Number: 730

Early Symptoms of Systemic Lupus Erythematosus As Reported By Members of the German Lupus Erythematosus Patient Association

9:00AM-11:00AM: Abstract Number: 784

Electronic Health Record (EHR) As a Powerful Tool to Establish Clinical Research Lupus Cohorts

9:00AM-11:00AM: Abstract Number: 767

Estimating the Pre-Test Probability of Systemic Lupus Erythematosus By Utilizing Anti-Double Stranded DNA and Cell Bound Complement Activation Products Testing from Rheumatology Based Practices in the United States

9:00AM-11:00AM: Abstract Number: 769

Evaluation of Soluble Alpha-Klotho in Neuropsychiatric Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 785

Further Validation of Simple Index As a Simple Disease Activity Assessment Tool for SLE

9:00AM-11:00AM: Abstract Number: 764

Gastrointestinal Adverse Events of Azathioprine in Daily Clinical Practice: Independent of Thiopurine Methyltransferase Activity

9:00AM-11:00AM: Abstract Number: 721

Geographic Differences in Demographics, Clinical Characteristics, and Standard of Care in Multinational Studies of Patients with Moderate to Severe Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 754

Glutathione S Transferases (GST) Polymorphisms Are Independents Predictors of Efficacy and Toxicity in Lupus Nephritis Treated with Cyclophosphamide

9:00AM-11:00AM: Abstract Number: 775

Identification of Candidate Items for Revised Classification Criteria for Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 788

Identification of Molecular Biomarkers to Distinguish Systemic Lupus Erythematosus with Skin Involvement from Discoid Lupus Erythematosus and Subacute Cutaneous Erythematosus: Provisional Results from Cross-Sectional Studies

9:00AM-11:00AM: Abstract Number: 742

IgM Antibodies Against Malondialdehyde and Phosphorylcholine Are T Cell Dependent and Strong Protection Markers for Atherosclerosis in SLE

9:00AM-11:00AM: Abstract Number: 760

Impact of Baseline Concomitant Medication Use on Belimumab Efficacy and Safety in Patients with Systemic Lupus Erythematosus (SLE)

9:00AM-11:00AM: Abstract Number: 791

Impact of Online Education and Social Media Intervetion for Self-Management in Adolescents with SLE

9:00AM-11:00AM: Abstract Number: 792

Incidence and Persistence of Cervical Human Papillomavirus Infection in Mexican Systemic Lupus Erythematosus Women

9:00AM-11:00AM: Abstract Number: 715

Investigating the Role of Vitamin D in Patients with SLE

9:00AM-11:00AM: Abstract Number: 733

Late Onset Systemic Lupus Erythematosus: A Different Disease Subset?

9:00AM-11:00AM: Abstract Number: 780

Long-Term Prognosis and Factors Associated with Damage Accrual in Japanese Patients with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 744

Longitudinal Assessment of Th1 and Th2 Cytokines: A Comparison Between Adult-Onset and Childhood-Onset Systemic Lupus Erythematous

9:00AM-11:00AM: Abstract Number: 763

Lupus-Related SNPs and Risk of Diffuse Large B-Cell Non-Hodgkin Lymphoma

9:00AM-11:00AM: Abstract Number: 779

Mapping Perceptions of Medication Decision Making Facilitators: The Importance of Patient Context

9:00AM-11:00AM: Abstract Number: 749

Microvesicles Containing Nucleic Acids and Expressing Immunoglobulins and HMGB1 Are Abundant in Patients with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 746

Multi-Center Delphi Exercise Reveals Important Key Items in Classifying SLE

9:00AM-11:00AM: Abstract Number: 724

Mycophenolate Mofetil in Non-Renal Manifestations of Systemic Lupus Erythematosus. an Observational Cohort Study

9:00AM-11:00AM: Abstract Number: 761

Neurometabolic Alterations in Korean Lupus Patients with Chronic Daily Headache

9:00AM-11:00AM: Abstract Number: 723

Oral Ulcers in Systemic Lupus Erythematosus: Characterization and Clarification of an Important Clinical Manifestation

9:00AM-11:00AM: Abstract Number: 783

Osteonecrosis in Systemic Lupus Erythematosus: Predictive Factors

9:00AM-11:00AM: Abstract Number: 772

Post-Phlebotomy Stability of Soluble and Cellular Forms of Complement Activation: Implications in SLE Diagnostic Assays

9:00AM-11:00AM: Abstract Number: 739

Prednisone Increases Both Arterial and Venous Thrombosis in SLE

9:00AM-11:00AM: Abstract Number: 759

Prolactin Level Is Independently Associated with Circulating CD4+CD28null in Systemic Lupus Erythematosus Patients

9:00AM-11:00AM: Abstract Number: 727

Repository Corticotropin Injection (H.P. Acthar® Gel) Attenuates Disease Activity in Patients with Persistently Active Systemic Lupus Erythematosus (SLE) Requiring Corticosteroids

9:00AM-11:00AM: Abstract Number: 751

Rituximab Induced Serum Sickness: A Systematic Review

9:00AM-11:00AM: Abstract Number: 738

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the BCL-2 Inhibitor Venetoclax (ABT-199) in a Phase 1 Single and Multiple Ascending Dose Study in Female Patients with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 741

Satisfaction and Impact Associated with the Addition of Belimumab to Systemic Lupus Erythematosus (SLE) Treatment: A Cross-Sectional Survey of US Rheumatologists and Their Patients

9:00AM-11:00AM: Abstract Number: 776

Sensitivity of Antinuclear Antibody By Immunofluorescence Testing for Detection of Anti-Ro/SSA Antibodies

9:00AM-11:00AM: Abstract Number: 753

Serum Levels of Tenascin-C Discriminate Patients with Active SLE from Inactive Patients and Healthy Controls, and Predict the Need to Escalate Immunosuppressive Therapy

9:00AM-11:00AM: Abstract Number: 777

SLE-KeyTM Rule-out Test to Assess Lupus in Anti-Nuclear Antibody Positive Subjects Using the Immunarray iCHIP®

9:00AM-11:00AM: Abstract Number: 717

Systemic Lupus Erythematosus and the Evaluation of Poor Sleep: The Sleeps Pilot Study

9:00AM-11:00AM: Abstract Number: 729

The Effect of Belimumab on Peripheral Blood Cells in Patients with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 762

The Interferon Signature Correlates with Longitudinal Disease Severity in Systemic Lupus Erythematosus, but Adds Little to Conventional Prognostic Indicators

9:00AM-11:00AM: Abstract Number: 768

The Lupus Foundation of America Rapid Evaluation of Activity in Lupus (LFA-REAL) Instrument Correlates Between Trained Clinical Investigators and Clinicians

9:00AM-11:00AM: Abstract Number: 740

The Prevalence of Anti-DFS70 Antibodies in an International Inception Cohort of Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 757

The Ratio Between TNF-a and P-Albumin – a Suggested Measure of Disease Activity in SLE

9:00AM-11:00AM: Abstract Number: 718

Urinary MBL : A Promising Biomarker for Predicting Flare in Lupus Nephritis

9:00AM-11:00AM: Abstract Number: 716

Urinary Proteomics Identifies Three Novel Biomarkers for Lupus Nephritis Activity: Retinol Binding Protein, Alpha-1-Antichymotrysin and Haptoglobin

9:00AM-11:00AM: Abstract Number: 755

Validating the RAIL Algorithm in Adult Lupus Nephritis Patients

9:00AM-11:00AM: Abstract Number: 787

Validation of Lupuspro V1.8, Disease Targeted Patient Reported Outcome for Systemic Lupus Erythematosus

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].